---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-26-001792"
form_type: "8-K"
ticker: "ENTXW"
cik: "0001638097"
company_name: "Entera Bio Ltd."
filed_at: "2026-03-27T23:59:59+00:00"
generated_at: "2026-05-15T08:38:36.102738+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Entera Bio FY2025 net loss $11.4M, cash runway to mid-Q3 2026; EB613 Phase 3 submitted

## Summary
- Net loss $11.4M ($0.25/sh) vs $9.5M in FY2024; R&D expenses $6.0M up from $4.5M.
- Cash $14.9M at Dec 31, 2025 incl. $7.8M restricted for OPKO collab; operating cash burn $7.4M.
- EB613 Phase 3 protocol submitted Mar 2026; FDA feedback expected late Apr 2026 with topline in H2 2028.
- EB612 (LA-PTH) collaboration with OPKO expanded; IND filing expected late 2026.
- EB618 (oral OXM) PK/PD validation complete; Phase 1 initiation dependent on injectable data by YE 2026.

## SEC filing metadata
- accession: 0001178913-26-001792
- form_type: 8-K
- ticker: ENTXW
- cik: 0001638097
- company_name: Entera Bio Ltd.
- filed_at: 2026-03-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1638097/000117891326001792/0001178913-26-001792-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1638097/000117891326001792/zk2634965.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-26-001792
- JSON: https://secwatch.observer/filing/0001178913-26-001792.json
- Plain text: https://secwatch.observer/filing/0001178913-26-001792.txt

## Key facts
- Earnings Releases
  Entera Bio Ltd. reported financial results for the year ended December 31, 2025.
  - Period: the year ended December 31, 2025
  - Result: reported results
  source text: On March 27, 2026, Entera Bio Ltd., a company organized under the laws of the State of Israel (“we,” “us,” “our” or the “Company”), issued a press release announcing its financial results for the year ended December 31, 2025 and business updates.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1638097/000117891326001792/0001178913-26-001792-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.